GENSCRIPT BIO (01548) Income Statement & Earnings

13.760
+0.010+0.07%

Market Closed Apr 17 16:07 CST

30.11BMarket Cap-7.26P/E (TTM)

GENSCRIPT BIO (01548) Income Statement

All

YOY

Hide blank lines

(FY)Dec 31, 2025

(Q6)Jun 30, 2025

(FY)Dec 31, 2024

(Q6)Jun 30, 2024

(FY)Dec 31, 2023

(Q6)Jun 30, 2023

(FY)Dec 31, 2022

(Q6)Jun 30, 2022

(FY)Dec 31, 2021

(Q6)Jun 30, 2021

Turnover

61.40%959.53M

81.92%518.77M

6.07%594.49M

-27.13%285.16M

-10.42%560.48M

26.40%391.31M

27.67%625.7M

34.86%309.59M

25.39%490.1M

37.97%229.57M

Operating income

61.40%959.53M

81.92%518.77M

6.07%594.49M

-27.13%285.16M

-10.42%560.48M

26.40%391.31M

27.67%625.7M

34.86%309.59M

25.39%490.1M

37.97%229.57M

Cost of sales

-26.05%-406.32M

-30.65%-198.14M

-11.22%-322.36M

29.87%-151.66M

9.88%-289.85M

-53.28%-216.26M

-54.94%-321.62M

-55.13%-141.09M

-53.82%-207.58M

-56.21%-90.95M

Operating expenses

-26.05%-406.32M

-30.65%-198.14M

-11.22%-322.36M

29.87%-151.66M

9.88%-289.85M

-53.28%-216.26M

-54.94%-321.62M

-55.13%-141.09M

-53.82%-207.58M

-56.21%-90.95M

Gross profit

103.29%553.2M

140.16%320.63M

0.55%272.13M

-23.73%133.51M

-11.00%270.63M

3.89%175.05M

7.63%304.08M

21.55%168.5M

10.40%282.52M

28.15%138.62M

Selling expenses

-12.90%-99.49M

-10.35%-47.51M

-9.96%-88.12M

47.11%-43.05M

52.40%-80.14M

6.37%-81.4M

-0.23%-168.35M

-49.21%-86.94M

-56.48%-167.97M

-41.92%-58.27M

Administrative expenses

-12.41%-128.57M

-19.71%-63.12M

-7.07%-114.38M

50.50%-52.73M

41.46%-106.82M

-33.73%-106.52M

-35.65%-182.46M

-41.44%-79.65M

-48.89%-134.51M

-54.85%-56.31M

Research and development expenses

-32.43%-71.23M

-25.74%-31.32M

-2.07%-53.79M

87.99%-24.91M

86.49%-52.7M

-16.74%-207.33M

-8.84%-390.1M

-1.41%-177.61M

-36.07%-358.4M

-51.69%-175.13M

Revaluation surplus

75.59%-30.16M

87.86%-13.78M

-195.65%-123.58M

-226.82%-113.51M

588.41%129.21M

24.21%-34.73M

113.46%18.77M

-2,764.00%-45.82M

-74.32%-139.43M

98.00%-1.6M

-Changes in the fair value of other assets

75.59%-30.16M

87.86%-13.78M

-195.65%-123.58M

-226.82%-113.51M

588.41%129.21M

24.21%-34.73M

113.46%18.77M

-2,764.00%-45.82M

-74.32%-139.43M

98.00%-1.6M

Impairment and provision

-661.95%-396.74M

101.01%417K

-216.78%-52.07M

-1,646.64%-41.34M

-30.15%-16.44M

-54.20%-2.37M

---12.63M

-24.70%-1.54M

----

---1.23M

-Other impairment is provision

-661.95%-396.74M

101.01%417K

-216.78%-52.07M

-1,646.64%-41.34M

-30.15%-16.44M

-54.20%-2.37M

---12.63M

-24.70%-1.54M

----

---1.23M

Operating interest expense

----

---3.3M

56.22%-2.38M

----

Special items of operating profit

11.10%40.13M

99.44%37.18M

11.94%36.12M

-25.76%18.64M

163.12%32.27M

835.07%25.11M

189.29%12.26M

-170.55%-3.42M

-54.41%4.24M

-56.10%4.84M

Operating profit

-7.41%-132.86M

264.10%202.49M

-170.28%-123.69M

46.86%-123.4M

142.06%176.01M

-1.05%-232.19M

18.90%-418.42M

-54.13%-229.78M

-83.40%-515.93M

5.74%-149.08M

Financing cost

-115.31%-17.29M

-181.49%-9.2M

-39.95%-8.03M

73.77%-3.27M

56.75%-5.74M

---12.46M

---13.27M

----

---1.14M

Share of profits of associates

-719.97%-320.38M

-15,237.51%-193.41M

-2,723.12%-39.07M

---1.26M

---1.38M

----

Special items of earning before tax

----

-20,614.29%-1.44M

----

Earning before tax

-175.49%-470.53M

99.91%-119K

-201.13%-170.8M

47.71%-127.93M

139.12%168.89M

-6.47%-244.65M

16.56%-431.69M

-52.96%-229.78M

-83.53%-517.36M

4.95%-150.22M

Tax

-1,978.30%-61.87M

-148.96%-24.43M

50.43%-2.98M

-788.77%-9.81M

-261.50%-6.01M

71.05%-1.1M

485.79%3.72M

35.65%-3.81M

-302.10%-964K

-140.66%-5.93M

After-tax profit from continuing operations

-206.38%-532.4M

82.18%-24.55M

-206.69%-173.77M

43.95%-137.74M

138.06%162.88M

-5.21%-245.76M

17.43%-427.97M

-49.59%-233.59M

-84.18%-518.33M

2.72%-156.15M

After-tax profit from non-continuing business

----

684.76%3.03B

---77.89M

---518M

----

Special items of earning after tax

----

684.76%3.03B

---77.89M

---518M

----

Earning after tax

-118.65%-532.4M

88.62%-24.55M

904.03%2.86B

12.26%-215.63M

17.02%-355.12M

-5.21%-245.76M

17.43%-427.97M

-49.59%-233.59M

-84.18%-518.33M

2.72%-156.15M

Minority profit

100.40%426K

102.26%915K

58.95%-106.59M

73.38%-40.52M

-29.10%-259.64M

-55.15%-152.18M

-26.00%-201.12M

-50.83%-98.08M

-108.71%-159.62M

-37.14%-65.03M

Profit attributable to shareholders

-117.99%-532.83M

85.46%-25.46M

3,202.19%2.96B

-87.13%-175.12M

57.91%-95.48M

30.94%-93.58M

36.76%-226.85M

-48.71%-135.51M

-75.03%-358.71M

19.43%-91.12M

Basic earnings per share

-117.60%-0.2458

85.73%-0.0118

3,182.34%1.3963

-86.26%-0.0827

58.13%-0.0453

31.48%-0.0444

38.77%-0.1082

-40.56%-0.0648

-63.91%-0.1767

23.29%-0.0461

Diluted earnings per share

-118.08%-0.2458

73.88%-0.0216

3,101.55%1.3597

-86.26%-0.0827

58.13%-0.0453

31.48%-0.0444

38.77%-0.1082

-40.56%-0.0648

-63.91%-0.1767

23.29%-0.0461

Currency Unit

USD

Accounting Standards

HKAS

Audit Opinions

Unqualified Opinion

Auditor

Ernst & Young

	(FY)Dec 31, 2025	(Q6)Jun 30, 2025	(FY)Dec 31, 2024	(Q6)Jun 30, 2024	(FY)Dec 31, 2023	(Q6)Jun 30, 2023	(FY)Dec 31, 2022	(Q6)Jun 30, 2022	(FY)Dec 31, 2021	(Q6)Jun 30, 2021
Turnover	61.40%959.53M	81.92%518.77M	6.07%594.49M	-27.13%285.16M	-10.42%560.48M	26.40%391.31M	27.67%625.7M	34.86%309.59M	25.39%490.1M	37.97%229.57M
Operating income	61.40%959.53M	81.92%518.77M	6.07%594.49M	-27.13%285.16M	-10.42%560.48M	26.40%391.31M	27.67%625.7M	34.86%309.59M	25.39%490.1M	37.97%229.57M
Cost of sales	-26.05%-406.32M	-30.65%-198.14M	-11.22%-322.36M	29.87%-151.66M	9.88%-289.85M	-53.28%-216.26M	-54.94%-321.62M	-55.13%-141.09M	-53.82%-207.58M	-56.21%-90.95M
Operating expenses	-26.05%-406.32M	-30.65%-198.14M	-11.22%-322.36M	29.87%-151.66M	9.88%-289.85M	-53.28%-216.26M	-54.94%-321.62M	-55.13%-141.09M	-53.82%-207.58M	-56.21%-90.95M
Gross profit	103.29%553.2M	140.16%320.63M	0.55%272.13M	-23.73%133.51M	-11.00%270.63M	3.89%175.05M	7.63%304.08M	21.55%168.5M	10.40%282.52M	28.15%138.62M
Selling expenses	-12.90%-99.49M	-10.35%-47.51M	-9.96%-88.12M	47.11%-43.05M	52.40%-80.14M	6.37%-81.4M	-0.23%-168.35M	-49.21%-86.94M	-56.48%-167.97M	-41.92%-58.27M
Administrative expenses	-12.41%-128.57M	-19.71%-63.12M	-7.07%-114.38M	50.50%-52.73M	41.46%-106.82M	-33.73%-106.52M	-35.65%-182.46M	-41.44%-79.65M	-48.89%-134.51M	-54.85%-56.31M
Research and development expenses	-32.43%-71.23M	-25.74%-31.32M	-2.07%-53.79M	87.99%-24.91M	86.49%-52.7M	-16.74%-207.33M	-8.84%-390.1M	-1.41%-177.61M	-36.07%-358.4M	-51.69%-175.13M
Revaluation surplus	75.59%-30.16M	87.86%-13.78M	-195.65%-123.58M	-226.82%-113.51M	588.41%129.21M	24.21%-34.73M	113.46%18.77M	-2,764.00%-45.82M	-74.32%-139.43M	98.00%-1.6M
-Changes in the fair value of other assets	75.59%-30.16M	87.86%-13.78M	-195.65%-123.58M	-226.82%-113.51M	588.41%129.21M	24.21%-34.73M	113.46%18.77M	-2,764.00%-45.82M	-74.32%-139.43M	98.00%-1.6M
Impairment and provision	-661.95%-396.74M	101.01%417K	-216.78%-52.07M	-1,646.64%-41.34M	-30.15%-16.44M	-54.20%-2.37M	---12.63M	-24.70%-1.54M	----	---1.23M
-Other impairment is provision	-661.95%-396.74M	101.01%417K	-216.78%-52.07M	-1,646.64%-41.34M	-30.15%-16.44M	-54.20%-2.37M	---12.63M	-24.70%-1.54M	----	---1.23M
Operating interest expense	----	----	----	----	----	----	----	---3.3M	56.22%-2.38M	----
Special items of operating profit	11.10%40.13M	99.44%37.18M	11.94%36.12M	-25.76%18.64M	163.12%32.27M	835.07%25.11M	189.29%12.26M	-170.55%-3.42M	-54.41%4.24M	-56.10%4.84M
Operating profit	-7.41%-132.86M	264.10%202.49M	-170.28%-123.69M	46.86%-123.4M	142.06%176.01M	-1.05%-232.19M	18.90%-418.42M	-54.13%-229.78M	-83.40%-515.93M	5.74%-149.08M
Financing cost	-115.31%-17.29M	-181.49%-9.2M	-39.95%-8.03M	73.77%-3.27M	56.75%-5.74M	---12.46M	---13.27M	----	----	---1.14M
Share of profits of associates	-719.97%-320.38M	-15,237.51%-193.41M	-2,723.12%-39.07M	---1.26M	---1.38M	----	----	----	----	----
Special items of earning before tax	----	----	----	----	----	----	----	----	-20,614.29%-1.44M	----
Earning before tax	-175.49%-470.53M	99.91%-119K	-201.13%-170.8M	47.71%-127.93M	139.12%168.89M	-6.47%-244.65M	16.56%-431.69M	-52.96%-229.78M	-83.53%-517.36M	4.95%-150.22M
Tax	-1,978.30%-61.87M	-148.96%-24.43M	50.43%-2.98M	-788.77%-9.81M	-261.50%-6.01M	71.05%-1.1M	485.79%3.72M	35.65%-3.81M	-302.10%-964K	-140.66%-5.93M
After-tax profit from continuing operations	-206.38%-532.4M	82.18%-24.55M	-206.69%-173.77M	43.95%-137.74M	138.06%162.88M	-5.21%-245.76M	17.43%-427.97M	-49.59%-233.59M	-84.18%-518.33M	2.72%-156.15M
After-tax profit from non-continuing business	----	----	684.76%3.03B	---77.89M	---518M	----	----	----	----	----
Special items of earning after tax	----	----	684.76%3.03B	---77.89M	---518M	----	----	----	----	----
Earning after tax	-118.65%-532.4M	88.62%-24.55M	904.03%2.86B	12.26%-215.63M	17.02%-355.12M	-5.21%-245.76M	17.43%-427.97M	-49.59%-233.59M	-84.18%-518.33M	2.72%-156.15M
Minority profit	100.40%426K	102.26%915K	58.95%-106.59M	73.38%-40.52M	-29.10%-259.64M	-55.15%-152.18M	-26.00%-201.12M	-50.83%-98.08M	-108.71%-159.62M	-37.14%-65.03M
Profit attributable to shareholders	-117.99%-532.83M	85.46%-25.46M	3,202.19%2.96B	-87.13%-175.12M	57.91%-95.48M	30.94%-93.58M	36.76%-226.85M	-48.71%-135.51M	-75.03%-358.71M	19.43%-91.12M
Basic earnings per share	-117.60%-0.2458	85.73%-0.0118	3,182.34%1.3963	-86.26%-0.0827	58.13%-0.0453	31.48%-0.0444	38.77%-0.1082	-40.56%-0.0648	-63.91%-0.1767	23.29%-0.0461
Diluted earnings per share	-118.08%-0.2458	73.88%-0.0216	3,101.55%1.3597	-86.26%-0.0827	58.13%-0.0453	31.48%-0.0444	38.77%-0.1082	-40.56%-0.0648	-63.91%-0.1767	23.29%-0.0461
Currency Unit	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD
Accounting Standards	HKAS	HKAS	HKAS	HKAS	HKAS	HKAS	HKAS	HKAS	HKAS	HKAS
Audit Opinions	Unqualified Opinion	--	Unqualified Opinion	--	Unqualified Opinion	--	Unqualified Opinion	--	--	--
Auditor	Ernst & Young	--	Ernst & Young	--	Ernst & Young	--	Ernst & Young	--	Ernst & Young	--

FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.

Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.

China and the United States have successively adjusted multiple tariff and non-tariff measures, beginning to implement the consensus outcome Show More

牛牛課堂

Oct 13, 2025 18:05

[Opportunity Express] The US-China rivalry escalates! The rare earth industry becomes a "game-changer." How should investors respond?

Food流油

Apr 14, 2025 15:43

"Leaving the Group - Raising Taxes - Tweeting: The 'Money Making Strategy' of the Most Wild Gemini in Contemporary Times"